Optical Genome Mapping ( <scp>OGM</scp> ): Validation and Clinical Utility in the Cytogenetic Diagnosis of Multiple Myeloma
Adela Cisneros(Josep Carreras Leukaemia Research Institute), Isabel Granada(Josep Carreras Leukaemia Research Institute), Yolanda González‐Montes(Institut Català d'Oncologia), Lourdes Escoda(Hospital Universitari Joan XXIII de Tarragona), Mar Mallo(Josep Carreras Leukaemia Research Institute), Albert Oriol(Universitat Autònoma de Barcelona), Encarnación Santafé(Institut Català d'Oncologia), Laura Abril(Institut Català d'Oncologia), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Françesc Solé(Fundación Josep Carreras Contra la Leucemia), Neus Ruiz‐Xivillé(Josep Carreras Leukaemia Research Institute), Carmen Villena(Institut Català d'Oncologia), Anna M. Sureda(Institut Català d'Oncologia), Jéssica Tijero(Universitat Autònoma de Barcelona), Xavier Ortı́n(Hospital Universitari de Tortosa Verge de la Cinta), Aleix Méndez‐López(Institut Català d'Oncologia), Gladys Ibarra(Institut Català d'Oncologia)
Cited by 1
Related Papers
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
|Journal of Clinical Oncology|2008|282
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
|Blood|2019|218
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients
|Blood|2013|189
Human immunodeficiency virus‐associated plasmablastic lymphoma
|Cancer|2012|178